Click Q2 2026 Earnings Report

Click EPS Results

• Actual EPS: $0.10
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Click Revenue Results

• Actual Revenue: $3.79 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Click Announcement Details

• Quarter: Q2 2026
• Date: 5/11/2026
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Click (NASDAQ:CLIK) Therapeutics, Inc. (NASDAQ: CLIK) is a clinical-stage digital therapeutics company developing software-based treatments for neurological, psychiatric and chronic diseases. Its platform delivers prescription digital therapies via mobile and web applications, combining evidence-based cognitive behavioral interventions, digital monitoring tools and patient engagement techniques. Click’s approach is designed to complement or extend traditional pharmacological and behavioral treatments for conditions such as major depressive disorder, insomnia and tobacco use disorder.

Founded in 2014, Click has progressed multiple programs through randomized controlled trials and regulatory review. Several of its lead digital therapeutics have earned Breakthrough Device designation from the U.S. Food and Drug Administration and have pursued CE marking for commercialization in Europe. The company collaborates with pharmaceutical partners, academic institutions and healthcare providers to integrate its digital products into clinical pathways and to collect real-world evidence supporting safety and efficacy.

Headquartered in New York City, Click operates in the United States with strategic alliances in select international markets. Its leadership team draws on deep experience in digital health innovation, neuroscience research and pharmaceutical development. Click continues to invest in research and development, aiming to expand its pipeline into new therapeutic areas and to scale adoption of its digital therapeutics globally.